Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616131 · ClinicalTrials.gov registry record
Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
A clinical trial, sponsored by Northwestern University.
- Recruiting
- Registry status
- 500
- Enrollment target
NCT04616131 is a clinical trial that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 500 participants.
The verdict
NCT04616131 is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2029-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04616131
The ClinicalTrials.gov registry entry for NCT04616131 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04616131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04616131 about?
NCT04616131 is a clinical study titled "Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy". For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.
What is the current status of trial NCT04616131?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2020-10-01. Estimated completion is 2029-10-01.
Who is sponsoring clinical trial NCT04616131?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.